In an adolescent after gross‑total resection of renal cell carcinoma, is sunitinib appropriate as adjuvant therapy?

Sunitinib is NOT Appropriate as Adjuvant Therapy in Adolescents After Renal Cell Carcinoma Resection

Sunitinib should not be used as adjuvant therapy in adolescents following gross-total resection of renal cell carcinoma, as it lacks FDA approval, safety data, and efficacy evidence in pediatric populations, and the risk-benefit profile is unfavorable even in adults.

Critical Evidence Gaps in Pediatric Populations

The FDA label for sunitinib explicitly indicates approval only for adult patients with adjuvant RCC treatment 1. There are no prospective trials, safety data, or dosing guidelines for adjuvant sunitinib in adolescents. The single published pediatric case involved metastatic relapsed disease (not adjuvant therapy), where a TFE3-translocation positive RCC responded to sunitinib 2. This represents treatment of active metastatic disease, not prevention of recurrence after complete resection—an entirely different clinical scenario.

Questionable Benefit Even in Adults

The evidence supporting adjuvant sunitinib in adults is controversial and limited:

• S-TRAC trial showed improved disease-free survival (6.8 vs 5.6 years, HR 0.76) but at significant cost: 48.4% experienced grade 3 adverse events, 12.1% had grade 4 events, 28.1% discontinued treatment, and overall survival benefit was not demonstrated 3, 4

• ASSURE trial failed to show benefit with adjuvant sunitinib in a similar population 5

• European Association of Urology guidelines explicitly recommend AGAINST adjuvant sunitinib in adults, citing conflicting evidence and unfavorable harm-to-benefit ratio 6

• EMA has NOT approved adjuvant sunitinib due to imbalance between risk and clinical benefit 7

Toxicity Concerns Amplified in Adolescents

The toxicity profile in adults is substantial and would be particularly concerning in adolescents:

• Dose reductions required in 34.3% of adults 3
• Treatment discontinuation in 28.1% due to adverse events 3
• Clinically meaningful increases in diarrhea and appetite loss affecting quality of life 8
• Hepatotoxicity requiring monitoring, with potential for severe or fatal outcomes 1
• Cardiovascular events including cardiomyopathy and hypertension 1

Adolescents may experience different pharmacokinetics, heightened sensitivity to growth and developmental effects, and long-term consequences that are poorly characterized.

Current Standard of Care

For completely resected localized RCC in any age group:

• Surveillance is the standard approach after gross-total resection 9, 10
• No adjuvant therapy has demonstrated overall survival benefit that justifies routine use
• Even in high-risk adult populations, the 2025 EAU guidelines note that adjuvant therapy remains investigational 9

Clinical Decision Algorithm

For an adolescent after gross-total RCC resection:

1. Confirm complete resection with negative margins
2. Establish risk stratification based on stage, grade, and histology
3. Implement active surveillance with imaging per institutional protocols
4. Reserve systemic therapy exclusively for documented recurrence or metastatic disease
5. If recurrence occurs, consider enrollment in pediatric oncology trials or multidisciplinary consultation regarding off-label targeted therapy

Common Pitfalls to Avoid

• Do not extrapolate adult adjuvant data to pediatrics—the S-TRAC trial enrolled only adults, and pediatric RCC has distinct biology (40% harbor TFE3 translocations) 2
• Do not confuse treatment of metastatic disease with adjuvant therapy—sunitinib has activity in metastatic RCC but preventing recurrence after complete resection is fundamentally different
• Do not underestimate toxicity burden—the quality of life impact and long-term effects in a developing adolescent are substantial considerations

The only appropriate role for sunitinib in adolescent RCC is treatment of documented metastatic or unresectable disease, not as adjuvant therapy after complete resection.